Back to search

Article

Prioritizing Combinational Drug Screening: A Ranking System for <i>In Vitro</i> Drug Combinations in Neurofibromatosis Type 1

2025-08-04

Abstract excerpt

Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by benign tumors, including plexiform neurofibromas, which can be difficult to treat. Currently, only two FDA-approved therapies exist: selumetinib, approved for pediatric patients with inoperable tumors, and mirdametinib, approved for patients aged two and older with symptomatic peripheral neuropathy where surgical resection is not possible. These...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dbdefda5-d154-5401-a2ce-fe71c09082ad
DOI
10.1101/2025.08.02.667047
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Prioritizing Combinational Drug Screening: A Ranking System for <i>In Vitro</i> Drug Combinations in Neurofibromatosis Type 1DOI 10.1101/2025.08.02.667047
Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and PotencySemantic proximity
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumorsSemantic proximity
Integrated <i>ex vivo</i> screening and transcriptomic profiling to prioritize drug combinations for rare cancersSemantic proximity
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaSemantic proximity
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2Semantic proximity
Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib TherapySemantic proximity
Integrative analysis identifies candidate tumor microenvironment and intracellular signaling pathways that define tumor heterogeneity in NF1Semantic proximity
[Interpretation of the Expert Consensus for Full Course Management of Plexiform Neurofibroma (2025 Edition)].Semantic proximity
A rapid platform for 3D patient-derived cutaneous neurofibroma organoid establishment and screeningSemantic proximity
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.Semantic proximity
Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.Semantic proximity
The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity <i>In vitro</i> and <i>In vivo</i>Semantic proximity
Select a neighboring publication to make it the new centre.